IL151646A0 - Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction - Google Patents

Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction

Info

Publication number
IL151646A0
IL151646A0 IL15164601A IL15164601A IL151646A0 IL 151646 A0 IL151646 A0 IL 151646A0 IL 15164601 A IL15164601 A IL 15164601A IL 15164601 A IL15164601 A IL 15164601A IL 151646 A0 IL151646 A0 IL 151646A0
Authority
IL
Israel
Prior art keywords
phosphodicesterase
pyrazinones
pyrido
inhibitors
erectile dysfunction
Prior art date
Application number
IL15164601A
Other languages
English (en)
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of IL151646A0 publication Critical patent/IL151646A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15164601A 2000-03-14 2001-03-06 Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction IL151646A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10012373A DE10012373A1 (de) 2000-03-14 2000-03-14 Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
PCT/EP2001/002485 WO2001068097A1 (de) 2000-03-14 2001-03-06 VERWENDUNG VON PYRIDO[3,2-e]-PYRAZINONEN ALS INHIBITOREN DER PHOSPHODIESTERASE 5 ZUR THERAPIE VON EREKTILER DYSFUNKTION

Publications (1)

Publication Number Publication Date
IL151646A0 true IL151646A0 (en) 2003-04-10

Family

ID=7634668

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15164601A IL151646A0 (en) 2000-03-14 2001-03-06 Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction

Country Status (14)

Country Link
EP (1) EP1267877A1 (bg)
JP (1) JP2003528056A (bg)
AR (1) AR028250A1 (bg)
AU (1) AU2001244192A1 (bg)
BG (1) BG107077A (bg)
BR (1) BR0109163A (bg)
CZ (1) CZ20023078A3 (bg)
DE (1) DE10012373A1 (bg)
HU (1) HUP0300551A2 (bg)
IL (1) IL151646A0 (bg)
NO (1) NO20024364L (bg)
RU (1) RU2002127413A (bg)
SK (1) SK13232002A3 (bg)
WO (1) WO2001068097A1 (bg)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
UA100126C2 (en) 2007-09-14 2012-11-26 Аддекс Фарма С.А. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
PT2200985E (pt) 2007-09-14 2011-07-21 Ortho Mcneil Janssen Pharm 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
EP2225248A1 (en) 2007-11-30 2010-09-08 Wyeth LLC Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
KR101753826B1 (ko) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,２,４―트리아졸로［４,３―ａ］피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2013192225A1 (en) * 2012-06-18 2013-12-27 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX2016009471A (es) 2014-01-21 2016-10-13 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso.
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
JP6420400B2 (ja) * 2017-04-12 2018-11-07 ダート・ニューロサイエンス・（ケイマン）・リミテッド 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
WO1993020077A1 (en) * 1992-04-03 1993-10-14 Yamanouchi Pharmaceutical Co., Ltd. Fused quinoxalinone derivative and pharmaceutical composition containing the same
DE4228095A1 (de) * 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
DE4338948A1 (de) * 1993-11-15 1995-05-18 Carlen Judith Verwendung von PDE-Inhibitoren bei der Behandlung erektiler Dysfunktionen
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
DE19728301A1 (de) * 1997-07-03 1999-01-07 Dresden Arzneimittel Verwendung von Inhibitoren der Phosphodiesterase 4 für die Behandlung der allergischen Rhinitis

Also Published As

Publication number Publication date
BG107077A (bg) 2003-05-30
RU2002127413A (ru) 2004-02-27
AR028250A1 (es) 2003-04-30
EP1267877A1 (de) 2003-01-02
WO2001068097A1 (de) 2001-09-20
NO20024364L (no) 2002-09-27
CZ20023078A3 (cs) 2003-03-12
JP2003528056A (ja) 2003-09-24
AU2001244192A1 (en) 2001-09-24
BR0109163A (pt) 2002-11-26
NO20024364D0 (no) 2002-09-12
SK13232002A3 (sk) 2003-05-02
HUP0300551A2 (hu) 2003-07-28
DE10012373A1 (de) 2001-09-20

Similar Documents

Publication Publication Date Title
IL151646A0 (en) Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction
IL138907A0 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
AU6116701A (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
HUP0200912A2 (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction
ZA200007019B (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence.
HUP0300477A3 (en) Daily treatment for erectile dysfunction using a composition containing pde5 inhibitors
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
EP1677754A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE EFFECTIVE DYSFUNCTION
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
EP1161255A4 (en) METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
IL154642A0 (en) Treatment of urinary dysfunction
WO2002041894A3 (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
AU2002246924A8 (en) Treatment of erectile dysfunction with rho-kinase inhibitors
IL162455A0 (en) Compounds for the treatment of sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
AU2001237379A1 (en) Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction
ZA200203069B (en) Peptides for treatment of erectile dysfunction.
EP1223957A4 (en) METHOD FOR TREATING ERECTILE DYSFUNCTION
EP1395593A4 (en) NEW PYRAZOLOPYRIMIDINTHION DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS A THERAPEUTIC IN ERECTILER DYSFUNCTION
AU2001281396A1 (en) Novel compositions and methods for treatment of male erectile dysfunction
ZA992793B (en) Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction.
AU2002219247A1 (en) Use of levosimendan for treating erictile dysfunction

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)

Owner name: ELBION GMBH

Free format text: FORMER NAME:ELBION AG